Focus: Neuronetics is a medical device company specializing in Transcranial Magnetic Stimulation (TMS) therapy for psychiatric and neurological disorders, with 5,000+ employees and public trading status (STIM ticker).
Profile data last refreshed 20h ago · AI intelligence enriched 1mo ago
Growing — net +14 jobs in 30d
42 jobs added vs 28 removed. Steady team buildout.
Neuronetics offers a rare blend of established device market presence and psychiatric expansion upside, but financial losses and M&A speculation warrant caution for stability-focused candidates.
Help build intelligence for Neuronetics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Neuronetics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Neuronetics Names CFO as Greenbrook Leadership Shifts - MyChesCo
Neuronetics Names CFO as Greenbrook Leadership Shifts MyChesCo
Neuronetics, Inc. (STIM) stock price, news, quote and history - Yahoo Finance Australia
Neuronetics, Inc. (STIM) stock price, news, quote and history Yahoo Finance Australia
STIM|Neuronetics Inc|Price:1.730|Chg%:-0.150 - TradingKey
STIM|Neuronetics Inc|Price:1.730|Chg%:-0.150 TradingKey
Neuronetics names Nir Naor CFO - Medical Buyer
Neuronetics names Nir Naor CFO Medical Buyer
Neuronetics Appoints Naor as CFO - Moomoo
Neuronetics Appoints Naor as CFO Moomoo
Neuronetics Names Nir Naor Chief Financial Officer, Announces Leadership Changes - citybiz
Neuronetics Names Nir Naor Chief Financial Officer, Announces Leadership Changes citybiz
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
A Multisite, 6-Month, Open-Label Study of Maintenance Transcranial Magnetic Stimulation for Adolescents with Treatment-Resistant Depression.
Comparison of clinical outcomes with left unilateral and sequential bilateral Transcranial Magnetic Stimulation (TMS) treatment of major depressive disorder in a large patient registry.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo